ERBB2 and breast cancer: T-DM1 is currently authorized for the use in patients with unresectable or metastatic HER2-positive BC who were previously treated with trastuzumab and taxane, or have relapsed during or within 6 months after the completion of the adjuvant therapy, based on the results of the phase III EMILIA trial [37].